BlossomHill Therapeutics (BLSM) Stock Price, News & Analysis

Company Overview

BlossomHill Therapeutics Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: $16.92 to $17.42
• 50-Day Range: $15.80 to $26.82
• 52-Week Range: $15.25 to $27.99
• Volume: 10,343 shs
• Average Volume: 219,297 shs
• Market Capitalization: $548.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Moderate Buy

BlossomHill Therapeutics Stock Analysis - MarketRank™

BlossomHill Therapeutics scored higher than 81% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BlossomHill Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

BlossomHill Therapeutics has a consensus price target of $35.00, representing about 100.2% upside from its current price of $17.48.

Amount of Analyst Coverage

BlossomHill Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BlossomHill Therapeutics are expected to grow in the coming year, from ($5.54) to ($3.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BlossomHill Therapeutics is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.49% of the float of BlossomHill Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

BlossomHill Therapeutics has a short interest ratio ("days to cover") of 1.62, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BlossomHill Therapeutics has recently increased by 244.42%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BlossomHill Therapeutics does not currently pay a dividend.

Dividend Growth

BlossomHill Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.67

News Sentiment

BlossomHill Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for BlossomHill Therapeutics this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for BLSM on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added BlossomHill Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

6 insiders have purchased shares of BlossomHill Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $25,181,900.00 in company stock, which represents 4.5331% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, BlossomHill Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,181,900.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

BlossomHill Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/18/2026
• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BLSM
• CIK: 1839970
• Web: bhtherapeutics.com
• Phone: 858-732-3880
• Fax: N/A
• Employees: 69
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BlossomHill Therapeutics: $35.00
• High Price Target: $40.00
• Low Price Target: $28.00
• Potential Upside/Downside: +100.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.42
• Quick Ratio: 5.42

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 31,780,000
• Free Float: N/A
• Market Cap: $555.51 million
• Optionable: N/A
• Beta: N/A